Cargando…
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
Autores principales: | Mehta, Puja, Porter, Joanna C, Chambers, Rachel C, Isenberg, David A, Reddy, Venkat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836835/ https://www.ncbi.nlm.nih.gov/pubmed/33521659 http://dx.doi.org/10.1016/S2665-9913(20)30270-8 |
Ejemplares similares
-
COVID-19 Vaccine in Children: Where Do We Stand?
por: Kumar, Jogender, et al.
Publicado: (2021) -
Topical Pramoxine in Chronic Pruritus: Where do We Stand?
por: Agarwal, Akash, et al.
Publicado: (2021) -
Monkeypox virus crosstalk with HIV; where do we stand now?
por: Shafaati, Maryam, et al.
Publicado: (2022) -
Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023) -
The need for pediatric indoor physical training guidelines during COVID-19 pandemic–related lockdown: where do we stand?
por: Arun Babu, Thirunavukkarasu
Publicado: (2022)